17 July 2020
Currently 26 variants of a vaccine against the coronavirus infection are being developed in Russia and the research results give assurance that their use will begin in the near future, Russian Deputy Prime Minister Tatyana Golikova reported on Wednesday.
As of today, according to the plan approved by the government 26 vaccine variants are being developed. <…> the research results <…> give rise to our confidence that already in the near future several effective vaccines at once will be used,” she said at a meeting of the anti-coronavirus coordinating council.
Golikova also expressed hope that the coronavirus vaccine of the Vector Center soon will obtain the permission to conduct clinical trials.
On July 14, the Russian Ministry of Health received from the Vector State Research Center of Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing the request for a permission to begin clinical trials of a vaccine against the novel coronavirus. According to Center’s General Director Rinat Maksyutov, registration of the first vaccine product is planned as early as the fall of this year.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024